Affimed N.V (AFMD)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Adolf Hoess |
| Employees: | 200 |
| Web site: | affimed.com |
|
IM NEUENHEIMER FELD 582, 69120, HEIDELBERG, 2M, 000000
49-6221-65307
| |
-
Formally known as:
- AFFIMED THERAPEUTICS B.V. COMMON
| Date | Ratio |
|---|---|
| 2024-03-11 | 1:10 |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Affimed N.V. focuses on discovering and developing cancer immunotherapies. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers.
Please log in first to see chart